IOVA - Iovance Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Iovance Biotherapeutics, Inc.

999 Skyway Road
Suite 150
San Carlos, CA 94070
United States

Full Time Employees88

Key Executives

NameTitlePayExercisedYear Born
Dr. Maria FardisCEO, Pres & Director1.11MN/A1968
Mr. Timothy E. MorrisCFO, Principal Accounting Officer, Corp. Sec. & Treasurer603kN/A1962
Dr. Frederick G. Vogt Ph.D., Esq.Gen. Counsel502.5kN/A1974
Mr. Howard B. JohnsonSr. VP of Corp. Devel., Alliance Management & Program ManagementN/AN/A1960
Dr. Friedrich Graf FinckensteinChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. The company is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. It has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Roswell Park Cancer Institute, MedImmune, and Genocea Biosciences, Inc.; and preclinical research collaboration with the Ohio State University and with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Corporate Governance

Iovance Biotherapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.